- In May 2024, Wockhardt, a global pharmaceutical and biotech company, announced the successful use of an investigational antibiotic under trial, Zidebactam/Cefepime, to treat a highly drug-resistant skull bone infection and pneumonia in a renal transplant patient. In this case, a 62-year-old man suffering from sino-pulmonary infection and skull base osteomyelitis, caused by NDM-producing Pseudomonas aeruginosa, a condition known for its high risk of complications, including neuroinfection, was treated successfully
- In September 2023, Orchid Pharma Ltd and the Global Antibiotic Research & Development Partnership (GARDP) entered into a sublicense agreement to produce cefiderocol, an antibiotic targeting specific Gram-negative infections. In this collaboration, part of a broader initiative led by GARDP, Shionogi & Co. Ltd., and the Clinton Health Access Initiative (CHAI), cefiderocol will be made more accessible in low- and middle-income countries, pending local or national regulatory approvals
- In November 2022, Clarametyx Biosciences Inc., a biotech company focused on developing targeted immune-enhancing biologics, officially began the clinical development of CMTX-101, an innovative immune-enhancing antibody therapy aimed at combating severe infections linked to biofilms. In this therapy, the technology targets bacterial biofilm structures, enhancing the effectiveness of antibiotics and immune treatments
- In December 2022, Clarametyx Biosciences initiated a Phase Ia clinical trial for CMTX-101, an immune-enabling antibody therapy, to treat community-acquired bacterial pneumonia
- In March 2022, the National Institute of Allergy and Infectious Diseases (NIAID) awarded approximately USD 2.5 million to two staff members from the University of Maryland School of Pharmacy (UMSOP) to study the development of multidrug resistance in infections caused by Pseudomonas aeruginosa
